+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Latin America Hyperphosphatemia Drugs Market 2019-2027

  • ID: 4791817
  • Report
  • Region: Latin America
  • 62 pages
  • Triton Market Research
1 of 3

FEATURED COMPANIES

  • Amag Pharmaceuticals
  • Bruno Farmaceutici S.P.A.
  • Fermenta Biotech, Ltd.
  • Johnson and Johnson
  • Royal Dsm N.V.
  • Shire
  • MORE
Market Outlook

According to this research, the hyperphosphatemia drugs market in Latin America is expected to proliferate with a CAGR of 17.20% in the forecast period of 2019-2027.

Brazil, Mexico and countries in rest of Latin America together constitute the hyperphosphatemia drugs market in the Latin American region.

Hyperphosphatemia is a condition that raises the phosphate levels in the blood. This condition can be caused because of the movement of phosphate from intracellular to extracellular space, unreasonable phosphate admission and diminishing in the discharge of phosphate. The elevated amounts of phosphate in the blood can be controlled by dietary limitations and with the utilization of phosphate binders. Hyperphosphatemia is an essential driver of bleakness and mortality in patients with persistent kidney illness. Hyperphosphatemia and expanded danger of death from cardiovascular sickness/vascular calcification are emphatically connected. This has expanded the danger of cardiovascular infection among the patients that have been reported to be suffering from hyperphosphatemia.

The rising prevalence of chronic diseases, increase in public awareness and the rise in the aging population are factors boosting the hyperphosphatemia drugs market. Furthermore, the growth of the market is propelled by the rising cases of osteoporosis and the changing dietary routine. However, non-adherence to treatment regiments, limited availability of drugs and use of advanced dialysis techniques are the key challenges faced by the market.

Competitive Outlook

The prominent players in the market are Zeria Pharmaceutical, Johnson and Johnson, Keryx Biopharmaceuticals, Inc., Sun Pharmaceutical Industries, Ltd., Royal DSM N.V., Cipla, Fermenta Biotech, Ltd., Roche Diagnostics Corporation, Sanofi, Ultragenyx Pharmaceutical, Inc., Fresenius Medical Care, Shire, Pfizer, Inc., AMAG Pharmaceuticals, Bio-Tech Pharmacal and Bruno Farmaceutici S.p.A.

Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Amag Pharmaceuticals
  • Bruno Farmaceutici S.P.A.
  • Fermenta Biotech, Ltd.
  • Johnson and Johnson
  • Royal Dsm N.V.
  • Shire
  • MORE
1. Latin America Hyperphosphatemia Drugs Market - Summary

2. Industry Outlook
2.1. Market Definition
2.2. Porter’s Five Force Model
2.2.1. Threat of New Entrants
2.2.2. Bargaining Power of Buyers
2.2.3. Bargaining Power of Suppliers
2.2.4. Threat of Substitute Product
2.2.5. Intensity of Competitive Rivalry
2.3. Vendor Scorecard
2.4. Key Buying Outlook
2.5. Key Insights
2.6. Key Market Trends
2.7. Guidelines Related to the Phosphate Binders
2.8. Market Drivers
2.8.1. Chronic Disorders are Increasing Rapidly
2.8.2. Increase in Public Cognizance
2.8.3. Increase in Geriatric Population
2.9. Market Restraints
2.9.1. Side-Effects Related to the Usage of Hyperphosphatemia Drugs
2.9.2. Strict Food and Drug Administration (Fda) Regulations
2.10. Market Opportunities
2.10.1. Rise in the Aging Population
2.11. Market Challenges
2.11.1. Alternative Dialysis Techniques
2.11.2. Accessibility of Drugs is Limited
2.11.3. Non-Adherence to Treatment Regimes

3. Hyperphosphatemia Drugs Market Outlook - By Dosages
3.1. Solid
3.1.1. Tablet
3.1.2. Powder
3.2. Liquid
3.2.1. Solution

4. Hyperphosphatemia Drugs Market Outlook - By Formulation
4.1.1. Calcium-Based Phosphate Binders
4.1.2. Aluminum-Based Phosphate Binders
4.1.3. Magnesium-Based Phosphate Binders
4.1.4. Iron-Based Phosphate Binders
4.1.5. Other Phosphate Binders

5. Hyperphosphatemia Drugs Market - Regional Outlook
5.1. Latin America
5.1.1. Country Analysis
5.1.1.1. Brazil
5.1.1.2. Mexico
5.1.1.3. Rest of Latin America

6. Competitive Landscape
6.1. Johnson and Johnson
6.2. Zeria Pharmaceutical
6.3. Amag Pharmaceuticals
6.4. Sanofi
6.5. Bruno Farmaceutici S.P.A.
6.6. Roche Diagnostics Corporation
6.7. Royal Dsm N.V.
6.8. Shire
6.9. Cipla
6.10. Ultragenyx Pharmaceutical, Inc.
6.11. Fermenta Biotech, Ltd.
6.12. Biotech Pharmacal
6.13. Sun Pharmaceutical Industries, Ltd.
6.14. Keryx Biopharmaceuticals, Inc.
6.15. Fresenius Medical Care
6.16. Pfizer, Inc.

7. Methodology & Scope
7.1. Research Scope
7.2. Sources of Data
7.3. Research Methodology

Table List
Table 1 Latin America Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Table 2 Phosphorous Levels in Select Foods
Table 3 Latin America Hyperphosphatemia Drugs Market By Formulation 2019-2027 ($ Million)
Table 4 Diagnosis and Clinical Indicators of Chronic Kidney Disease
Table 5 Latin America Hyperphosphatemia Drugs Market Country Analysis 2019-2027 ($ Million)

Figure List
Figure 1 Porter’s Five Forces Model of Hyperphosphatemia Drugs Market
Figure 2 Iron-Based Hyperphosphatemia Drug Approval Status 2014-2017
Figure 3 Rate of Adherence to Phosphate Binders
Figure 4 Latin America Hyperphosphatemia Drugs Market in Calcium-Based Phosphate Binders 2019-2027 ($ Million)
Figure 5 Latin America Hyperphosphatemia Drugs Market in Aluminum-Based Phosphate Binders 2019-2027 ($ Million)
Figure 6 Latin America Hyperphosphatemia Drugs Market in Magnesium-Based Phosphate Binders 2019-2027 ($ Million)
Figure 7 Latin America Hyperphosphatemia Drugs Market in Iron-Based Phosphate Binders 2019-2027 ($ Million)
Figure 8 Latin America Hyperphosphatemia Drugs Market in Other Phosphate Binders 2019-2027 ($ Million)
Figure 9 Latin America Hyperphosphatemia Drugs Market Share 2018 & 2027 (%)
Figure 10 Latin America Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 11 Brazil Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 12 Mexico Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 13 Rest of Latin America Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Johnson and Johnson
  • Zeria Pharmaceutical
  • Amag Pharmaceuticals
  • Sanofi
  • Bruno Farmaceutici S.P.A.
  • Roche Diagnostics Corporation
  • Royal Dsm N.V.
  • Shire
  • Cipla
  • Ultragenyx Pharmaceutical, Inc.
  • Fermenta Biotech, Ltd.
  • Biotech Pharmacal
  • Sun Pharmaceutical Industries, Ltd.
  • Keryx Biopharmaceuticals, Inc.
  • Fresenius Medical Care
  • Pfizer, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll